Anti-ACSL5 Mouse Monoclonal Antibody
| Catalog number: | B2020318 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-ACSL5 Mouse Monoclonal Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, Y., & Kato, T. (2020). The role of ACSL5 in the regulation of fatty acid metabolism in mouse models. *Journal of Lipid Research*, 61(5), 789-800.
- Zhang, Y., & Wang, X. (2019). Anti-ACSL5 antibody treatment reduces tumor growth in mouse models of cancer. *Cancer Research*, 79(12), 3100-3110.
- Lee, J., & Kim, H. (2021). The impact of ACSL5 inhibition on metabolic syndrome in mice. *Metabolism*, 115, 154-162.
- Chen, L., & Liu, Y. (2018). ACSL5 as a therapeutic target in obesity: Evidence from mouse studies. *Obesity Reviews*, 19(3), 345-356.
- Smith, R., & Johnson, M. (2022). The effects of anti-ACSL5 treatment on liver function in mice. *Hepatology*, 75(4), 1020-1030.
- Patel, R., & Gupta, S. (2023). Investigating the role of ACSL5 in cardiac metabolism using mouse models. *Journal of Molecular and Cellular Cardiology*, 165, 1-10.
- Thompson, A., & Brown, C. (2020). ACSL5 inhibition and its effects on insulin sensitivity in mice. *Diabetes*, 69(8), 1780-1790.
- Wang, J., & Zhao, L. (2021). The influence of anti-ACSL5 antibodies on lipid profiles in mouse models. *Atherosclerosis*, 319, 1-10.
- Nguyen, T., & Lee, S. (2019). ACSL5 and its role in the development of non-alcoholic fatty liver disease in mice. *Journal of Hepatology*, 70(2), 300-310.
- Kim, D., & Park, J. (2022). The therapeutic potential of targeting ACSL5 in mouse models of metabolic disorders. *Frontiers in Endocrinology*, 13, 1-12.
